Paper Details

  1. Home
  2. Paper Details

Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers.

Author: BansalNivedita, BentleyMatthew, BourgeoisA Louis, CarpenterColleen M, ChatfieldSteve, FidlerChristine, HamletSandra, HindleZoë, KirkpatrickB D, KutzkoDeborah, LaPointeCasey, LarssonCatherine J, MakinJill, McKenzieRobin, O'NeillJ Patrick, RobinsonBrad E, ShimkoJanet, TaylorDavid N, VentroneCassandra H

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study evaluates the safety and immunogenicity of a single oral dose of M01ZH09, a live, attenuated, oral typhoid vaccine harboring SPI-2 mutations. The study found that M01ZH09 was well-tolerated and immunogenic, with the highest dose being the most effective. The study suggests that M01ZH09 is a promising typhoid vaccine candidate and could be further developed as a vectoring system for heterologous antigens.
Paper Details　
Original Abstract of the Article :
Salmonella enterica serovar Typhi strains with mutations in the Salmonella pathogenicity island-2 (SPI-2) may represent an effective strategy for human vaccine development, and a vectoring system for heterologous antigens. S. Typhi (Ty2 aroC-ssaV-) M01ZH09 is an attenuated, live, oral typhoid vaccin...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.vaccine.2005.08.008

データ提供：米国国立医学図書館（NLM）

A New Typhoid Vaccine: Hope on the Horizon

The development of effective vaccines is a cornerstone of public health. This study investigates the potential of a novel typhoid vaccine, S. Typhi (Ty2 aroC-ssaV-) M01ZH09, which utilizes a defined mutation in the Salmonella pathogenicity island 2 (SPI-2). This vaccine has shown promise as a safe and immunogenic option for preventing typhoid fever, a serious bacterial infection.

The Promise of a Single-Dose Vaccine: A New Era in Typhoid Prevention

The researchers conducted a clinical trial in healthy adult volunteers to assess the safety and immunogenicity of a single dose of M01ZH09. The findings were encouraging, showing that the vaccine was well-tolerated and induced a strong immune response. This suggests that M01ZH09 could potentially revolutionize typhoid vaccination by simplifying the administration process and enhancing efficacy.

A Potential Breakthrough: A New Weapon Against Typhoid

This study offers hope for the development of a more effective and convenient typhoid vaccine. The potential of M01ZH09, with its single-dose administration and promising immunogenicity, could significantly improve global health efforts to combat typhoid fever. Continued research and development are crucial to translate this promising candidate into a widely available and impactful vaccine.

Dr.Camel's Conclusion

This study is like a camel caravan venturing into a new territory, seeking a solution to the age-old threat of typhoid fever. The promising results of M01ZH09 suggest a potential breakthrough in vaccine development, offering hope for a healthier future.

Date :
  1. Date Completed 2006-04-28
  2. Date Revised 2006-05-19
Further Info :

Pubmed ID

16140433

DOI: Digital Object Identifier

10.1016/j.vaccine.2005.08.008

Related Literature

Article Analysis
・Effects of typhoid vaccine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.